Showing 7031-7040 of 8649 results for "".
- Rayner Completes Recruitment for RayOne Galaxy IDE Studyhttps://modernod.com/news/rayner-completes-recruitment-for-rayone-galaxy-ide-study/2482642/Rayner announced the closure of recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy IOL in the United States. Developed in collaboration with Brazilian ophthalmologist João Lyra, MD, PhD, RayOne Galaxy is the worl
- SeaBeLife Reports Promising In Vivo Results for Ophthalmic Gel Candidate for GAhttps://modernod.com/news/seabelife-reports-promising-in-vivo-results-for-it-ophthalmic-gel-candidate-for-ga/2482635/SeaBeLife announced in vivo results for its SBL03 drug candidate, an ophthalmic gel designed to combat necrotic retinal cell death in geographic atrophy (GA). The primary objective of the preclinical study was to assess
- Heidelberg Hosts First International Glaucoma Symposiumhttps://modernod.com/news/heidelberg-hosts-first-international-glaucoma-symposium/2482628/The first International Glaucoma Symposium will be held by Heidelberg Engineering in conjunction with Mainz University on February 1, 2025. Bringing together specialists from around the world, the symposium calls for AI to be fully implemented as an increasing number of glaucoma and dia
- Nacuity Pharmaceuticals Granted FDA Fast Track Designation for NPI-001 Tablets for RPhttps://modernod.com/news/nacuity-pharmaceuticals-granted-fda-fast-track-designation-for-npi-001-tablets-for-retinitis-pigmentosa/2482625/Nacuity Pharmaceuticals announced that the FDA has granted Fast Track Designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy for the treatment of patients with retinitis pigmentosa (RP). A drug may receive Fast Track designation
- Specialty Contact Lens Division WAVE Eye Care Formedhttps://modernod.com/news/specialty-contact-lens-division-wave-eye-care-formed/2482616/EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System—three providers of specialty contact lens fitting—have united to form WAVE Eye Care, a division dedicated to providing fully customized specialty contact lenses. According to a j
- Bausch + Lomb Makes Two Deals to Bolster Therapeutic Pipeline in GA and Glaucomahttps://modernod.com/news/bausch-lomb-makes-two-deals-to-bolster-therapeutic-pipeline-in-ga-and-glaucoma/2482612/Bausch + Lomb announced two separate deals to acquire early- and mid-stage therapeutic assets. First, B+L, through an affiliate, acquired Whitecap Biosciences LLC, which is developing two therapies for potential use in glaucoma and geographic atrophy (GA). Financial terms
- Lumibird Medical Rebrands its Japanese Subsidiaryhttps://modernod.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/Lumibird Medical has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective immediately. Founded in Osaka in 2003, the subsidiary has grown over the past two decades,&nbs
- Prevent Blindness Provides Free Glaucoma Resources to Patients, Care Partners, and Professionalshttps://modernod.com/news/prevent-blindness-provides-free-glaucoma-resources-to-patients-care-partners-and-professionals/2482593/As part of January’s National Glaucoma Awareness Month, the non-profit Prevent Blindness is offering free educational resources to patients, care partners, and professionals. The resources include downloadable
- New Museum of the Eye Exhibit Brings Images to Life for the Visually Impaired and Blindhttps://modernod.com/news/new-museum-of-the-eye-exhibit-brings-images-to-life-for-the-visually-impaired-and-blind/2482592/The Truhlsen-Marmor Museum of the Eye introduced a tactile exhibit to improve accessibility and inclusion for those who are blind and visually impaired.
- Celltrion Receives Positive CHMP Opinion for Eylea Biosimilar in the European Unionhttps://modernod.com/news/celltrion-receives-positive-chmp-opinion-for-eylea-biosimilar-in-the-european-union/2482586/Celltrion announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions and recommended marketing authorizations for three biosimilar candidates, including Eydenzelt (CT-P42, aflibercept). Eydenzel